Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
CRediT author statement

Alyaa Elhazmi: conceptual design, data collection, data analysis. Helped with the first draft of the manuscript
Jaffar A. Al-Tawfiq: conceptual design, data analysis, drafted the first manuscript
Hend Sallam: data collection, data analysis
Awad Al-Omari: conceptual design, data collection, data analysis
Saad Alhumaid: data collection, data analysis
Ahmad Mady: data collection, data analysis
Abbas Al Mutair: conceptual design, data collection, data analysis, Helped with the first draft of the manuscript

All authors finalized and approved the final draft of the manuscript
Severe Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Coinfection: A Unique Case Series

Alyaa Elhazmi¹, Jaffar A. Al-Tawfiq²,³,⁴*, Hend Sallam⁵, Awad Al-Omari⁶,⁷, Saad Alhumaid⁸, Ahmad Mady⁹,¹⁰, Abbas Al Mutair¹¹,¹²

¹Adult Critical care department, Dr. Sulaiman Alhabib medical group, Riyadh, Saudi Arabia (a.m.haz@live.com); ²Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; ³Infectious Disease Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; ⁴Infectious Disease Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; ⁵Adult critical care medicine, King Faisal specialist hospital and research Centre, Riyadh, Saudi Arabia (Hsallam@kfshrc.edu.sa); ⁶Research Center, Dr Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia; ⁷College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; ⁸Administration of Pharmaceutical Care, Ministry of Health, Al-Ahsa, Saudi Arabia (saalhumaid@moh.gov.sa); ⁹Critical Care Department, King Saud Medical City, Riyadh, Saudi Arabia; ¹⁰Department of Anesthesiology and ICU, Tanta University Hospitals, Tanta, Egypt; ¹¹Almoosa Specialist Hospital, Al-Ahsa, Saudi Arabia; ¹²School of Nursing, Wollongong University, Australia

*Corresponding author:

Dr. Jaffar A. Al-Tawfiq

P.O. Box 76; Room A-428-2, Building 61, Dhahran Health Center, Saudi Aramco, Dhahran 31311, Saudi Arabia.

E-mail address: jaffar.tawfiq@jhah.com; jaltawfi@yahoo.com
Abstract:

Introduction: The emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) had raised possibilities of coinfection with the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in countries were these two viruses were reported. In this study, we describe the clinical presentation and demographics of eight patients who were coinfected with SARS-CoV-2 and MERS-CoV.

Materials and Methods: This is a case series of hospitalized patients admitted to Saudi intensive care units (ICUs). We collected demographics, underlying conditions, presenting symptoms and clinical outcome from the patients’ medical records.

Results: During the study period from March 14, 2020 to October 19, 2020, there was a total of 67 SARS-CoV-2 ICU admitted patients who underwent simultaneous SARS-CoV-2 and MERS-CoV testing. Of those patients, 8 (12%) tested positive for both SARS-CoV-2 and MERS-CoV. There were 6 (75%) males, the mean age ± SD was 44.4 ± 11.8 years, and 7 (87.5%) were obese. Of the patients, 7 (87.5%) were non-smokers, 1 (12.5%) had diabetes mellitus, 1 (12.5%) had heart failure, and 1 (12.5%) had been on anti-platelet therapy. The mean hospital length of stay (LOS) was 21.1 ± 11.6 days and the average ICU LOS was 10.9 ± 6.03 days. All patients received supportive therapy and all were treated with corticosteroid. Of all the patients, 4 (50%) were discharged home and 3 (37.5%) died.

Conclusion: This case series is an important addition to the medical knowledge as it showed the interaction of the coinfection of SARS-CoV-2 and MERS-CoV.

Keywords: COVID-19; SARS-CoV-2; MERS-CoV; coinfection
Introduction:

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and had caused the current CoronaVirus Disease 19 (COVID-19) pandemic. COVID-19 had been associated with tremendous medical challenges as well as societal and industrial interruption [1]. COVID-19 clinical presentation ranges from asymptomatic to severe disease [2–6]. And the case fatality rate of COVID-19 is variable [7,8]. The clinical characteristics of the disease in Saudi Arabia is similar to other reported presentations [4–6,8,9].

Recently, there had been few reports of coinfection of different micro-organisms with SARS-CoV-2. Coinfections with SARS-CoV-2 were reported with influenza, other respiratory pathogens, herpes simplex virus (HSV) and human immune deficiency virus (HIV) [10–15]. In the Kingdom of Saudi Arabia (KSA), the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is of particular concern as KSA is the country where MERS-CoV had been initially identified in 2012 [16–18]. One particular characteristic of MERS-CoV is the ability to cause healthcare associated outbreaks [19–21].

In addition, MERS-CoV is of particular importance as it has about 35% case fatality rate [22].

The first case of COVID-19 was reported in Saudi Arabia on March 2nd, 2020 [6,9]. However, we are not aware of any reports of coinfection of SARS-CoV-2 and MERS-CoV. In an initial cohort of 99 patients of SARS-CoV-2, none of them had coinfection with MERS-CoV [23]. Here, we describe the clinical and demographics of patients who were coinfected with SARS-CoV-2 and MERS-CoV.

Materials and Methods:

This is a case series of hospitalized cases admitted to Saudi intensive care units (ICUs) from March 14, 2020 to October 19, 2020. We collected demographics, underlying conditions,
presenting symptoms and clinical outcome from the patients’ medical records. Nasopharyngeal swabs were tested for the presence of MERS-CoV upE and orf1a [24,25] and for SARS-CoV-2 E and S genes using the RealStar® SARS-CoV-2 real-time Reverse Transcriptase PCR (RT-PCR) as described previously [6,23,26]. The study was approved by the IRB of the Central IRB of Ministry of Health (Log No: 20-80E).

Results:

Case Summaries:

During the study period, there was a total of 67 SARS-CoV-2 patients who were admitted to the ICUs and underwent simultaneous SARS-CoV-2 and MERS-CoV testing at the discretion of the treating physician. Of those patients, 8 (12%) tested positive for both SARS-CoV-2 and MERS-CoV.

Demographics and Clinical Characteristics:

Of the eight patients, there were 6 (75%) males. The mean age ± SD was 44.4 ± 11.8 years and the mean Body Mass Index (BMI) was 31 ± 4.7. Based on BMI, 1 (12.5%) had normal BMI and 7 (87.5%) were obese and these were 2 (25%) were overweight (BMI 25-29.9), 3 (36.5%) were obese (BMI: 30-34.9), and 2 (25%) were extreme obesity (BMI: > 35) (Table 1).

One patient (12.5%) was Saudi and 1 (12.5%) was a healthcare worker. Of the patients, 7 (87.5%) were non-smokers, 1 (12.5%) had diabetes mellitus, 1 (12.5%) had heart failure, and 1 (12.5%) had anti-platelet therapy. None of the patients had hypertension, ischemic heart disease, COPD, asthma, liver disease; hemoglobinopathy; CKD; renal replacement; immunocompromised; transplant; malignancy; or recent surgery.

Symptoms:
All patients had shortness of breath, 2 (25%) had runny nose, 4 (50%) had gastrointestinal (GI) symptoms, and 7 (87.5%) had history of fever. Altered consciousness/confusion was present in 1 (12.5%), cough in 7 (87.5%), abdominal pain in 6 (75%), headache in 1 (12.5%), chest pain in 1 (12.5%), arthralgia, myalgia, and fatigue each was present in 12.5%, and sore throat in 3 (37.5%).

**Hospital Course:**

The initial mean and SD of laboratory tests are shown in table 2. The mean hospital length of stay was 21.1 ± 11.6 days, the average ICU length of stay (LOS) was 10.9 ± 6.03 days. The initial mode of oxygen delivery was face mask (1; 12.5%), non-rebreather mask (NRM) (4; 50%), and mechanical ventilation (3; 37.5%). However, eventually 7 (87.5%) required mechanical ventilation and the average duration of mechanical ventilation was 6.67 (± 5.9) days.

All patients received supportive therapy and all were treated with corticosteroid. There was no specific anti-viral therapy. Of all the patients, 1 (12.5%) was transferred to another facility, 4 (50%) were discharged home and 3 (37.5%) died.

**Discussion:**

This case series is a unique contribution to the medical literature by examining the coinfection of two emerging respiratory pathogens MERS-CoV and SARS-CoV-2. These two viruses had the chance to cause significant disease in the Kingdom of Saudi Arabia. The country had gained great experience from previous MERS-CoV infection and had adopted a significant infection control and preventative measures [27]. Coinfection of SARS-CoV-2 and other respiratory viruses had been reported [10–15]. In addition, there few cases of coinfection of MERS-CoV and influenza or tuberculosis [28,29]. Here, we report the coinfection of MERS-CoV and SARS-CoV-2. In an initial cohort of 99 cases who were tested simultaneously for
MERS-CoV and SARS-CoV-2, none of them had SARS-CoV-2 and MERS-CoV coinfection [23]. In this study, 12% of the tested patients were positive for both SARS-CoV-2 and MERS-CoV. It was reported that in the past few years, MERS-CoV positivity rates among suspected cases was 2–6% [30].

The included patients were relatively young. Previously, the mean age of COVID-19 patients in Saudi Arabia was 36-50 years [6,31] and a median age 44 years [23]. The presence of comorbidities in patients with SARS-CoV-2 ranges from 32% to 93% in different studies [32–34]. One half of the included patients had gastrointestinal symptoms. Previously, gastrointestinal symptoms were reported in 33% of MERS-CoV patients [24,25,35–38], and 29% of COVID-19 patients had gastrointestinal symptoms [39] and another study showed higher rate of diarrhea in elderly patients [40]. In addition, the majority of hospitalized MERS-CoV patients had fever, cough and shortness of breath in addition to pneumonia on chest x-ray [24,25,35,41].

This case series showed that 37.5% of ICU coinfected patients had died. Previous studies of MERS-CoV showed a case fatality rate of 30% with increasing rate among those with comorbidities [24], critical ill patients, severe disease, those > 65 years of age, hospital-acquired infections and corticosteroid use [35,42–48]. However, the use of corticosteroid is associated with decreased case fatality rate in randomized controlled trials of COVID-19 patients from 25.7% in standard therapy to 22.9% in the dexamethasone group [49]. In addition, there is a variation in the fatality rates among different countries and different time intervals and ranged from 60% in March 2020 to 42% in May 2020 [50]. The Epidemiology of MERS-CoV infection is Saudi Arabia is well characterized by sporadic cases from Camel exposure followed by either hospital [19–21] or community transmission [51–53]. However, we were not able to pinpoint the exact exposure of infection of the included patients.
The initial laboratory findings of the included patients showed normal WBC and lymphocyte counts. However, the mean ± SD of the neutrophils to lymphocyte count ratio (NLCR) was 10.14 (8.77). The NLCR of ≥3.13 is a predictor of ICU admission and a marker of disease severity [32]. A previous study from Saudi Arabia showed that NLCR was significantly higher among ICU admissions than other patients [6]. We did not examine the duration of viral shedding in this study. A previous meta-analysis showed that the mean shedding duration of MERS-CoV was 15·3 days in the upper respiratory tract and 16·3 days in the lower respiratory tract. On the other hand, in COVID-19 patients the shedding of SARS-CoV-2 had a mean duration of 17 days in upper respiratory tract and 14·6 days in lower respiratory tract [54]. It was stated that SARS-CoV-2 viral loads peak about 10 days after symptoms onset [55,56].

In conclusion, this case series is important as it showed the interaction of the coinfection of SARS-CoV-2 and MERS-CoV. However, in this small case-series the combined infection was not associated with increased risk of death in comparison with mono-infection with MERS-CoV. However, as there was one patient who is transferred to another facility and lost to follow-up and if that patient died then the mortality would be 50%. Thus, additional studies are required to confirm or refute this finding and it is not possible to draw a firm conclusion about the mortality in co-infected MERS-CoV and SARS-CoV-2 patients. The presenting symptoms and laboratory data are not different from each of the infection alone. Although, 7 (87.5%) were in the ICU, a conclusion could not be drawn as all screened patients for MERS and SARS-CoV-2 were from those patients who were admitted to the ICU. With the continued COVID-19 pandemic, there is a continued need to continue precautionary measures including social distancing and universal masking. These measures continued to be enforced in the Kingdom of
Saudi Arabia [9,57]. Moreover, KSA implemented universal masking in public and common areas. These measures are important for the control of COVID-19 [58,59].
References:

[1] Al-Tawfiq JA, Al-Yami SS, Rigamonti D. Changes in healthcare managing COVID and non–COVID-19 patients during the pandemic: striking the balance. Diagn Microbiol Infect Dis 2020;98. doi:10.1016/j.diagmicrobio.2020.115147.

[2] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;6736:1–9. doi:10.1016/S0140-6736(20)30566-3.

[3] Nicastri E, D’Abramo A, Faggioni G, De Santis R, Mariano A, Lepore L, et al. Coronavirus disease (COVID-19) in a paucisymptomatic patient: Epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020. Eurosurveillance 2020;25. doi:10.2807/1560-7917.ES.2020.25.11.2000230.

[4] Al-Omari A, Alhuqbani WN, Zaidi ARZ, Al-Subaie MF, AlHindi AM, Abogosh AK, et al. Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia: A descriptive cross-sectional study. J Infect Public Health 2020. doi:10.1016/j.jiph.2020.09.003.

[5] Al Mutair A, Alhumaid S, Alhuqbani WN, Zaidi ARZ, Alkoraisi S, Al-Subaie MF, et al. Clinical, epidemiological, and laboratory characteristics of mild-to-moderate COVID-19 patients in Saudi Arabia: an observational cohort study. Eur J Med Res 2020;25:61. doi:10.1186/s40001-020-00462-x.

[6] AlJishi JM, Alhajjaj AH, Alkhabbaz FL, Alabduljabar TH, Alsai A, Alsai H, et al. Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia. J Infect Public Health 2021;14:6–11. doi:10.1016/j.jiph.2020.11.002.
[7] Tirupathi R, Muradova V, Shekhar R, Salim SA, Al-Tawfiq JA, Palabindala V. COVID-19 disparity among racial and ethnic minorities in the US: A cross sectional analysis. Travel Med Infect Dis 2020;38:101904. doi:10.1016/j.tmaid.2020.101904.

[8] Al-Tawfiq JA, Leonardi R, Fasoli G, Rigamonti D. Prevalence and fatality rates of COVID-19: What are the reasons for the wide variations worldwide? Travel Med Infect Dis 2020;35:101711. doi:10.1016/j.tmaid.2020.101711.

[9] Al-Tawfiq JA, Sattar A, Al-Khadra H, Al-Qahtani S, Al-Mulhim M, Al-Omoush O, et al. Incidence of COVID-19 among returning travelers in quarantine facilities: A longitudinal study and lessons learned. Travel Med Infect Dis 2020;38. doi:10.1016/j.tmaid.2020.101901.

[10] ML T, YQ L, X C, H L, ZC J, DL G, et al. Co-Infection with Common Respiratory Pathogens and SARS-CoV-2 in Patients with COVID-19 Pneumonia and Laboratory Biochemistry Findings: A Retrospective Cross-Sectional Study of 78 Patients from a Single Center in China. Med Sci Monit 2021;27. doi:10.12659/MSM.929783.

[11] Thuy-Boun PS, Mehta S, Gruening B, McGowan T, Nguyen A, Rajczewski AT, et al. Metaproteomics Analysis of SARS-CoV-2-Infected Patient Samples Reveals Presence of Potential Coinfecting Microorganisms. J Proteome Res 2021:acs.jproteome.0c00822. doi:10.1021/acs.jproteome.0c00822.

[12] Hashemi SA, Safamanesh S, Zadeh-moghaddam HG, Ghafoori M, Azimian A. High prevalence of SARS-CoV-2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran. J Med Virol 2020. doi:10.1002/jmv.26364.

[13] Lew S, Manes P, Smith B. Coinfection with sars-cov-2 and influenza a virus in a 32-year-old man. Am J Case Rep 2020;21:1–5. doi:10.12659/AJCR.926092.
[14] Alharthy A, Faqihi F, Noor A, Memish Z, Karakitsos D. Co-infection of human immunodeficiency virus, herpes simplex virus-2 and SARS-CoV-2 with false-negative real-time polymerase chain reaction. Singapore Med J 2020. doi:10.11622/smedj.2020158.

[15] Byrd KM, Beckwith CG, Garland JM, Johnson JE, Aung S, Cu-Uvin S, et al. SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States. J Int AIDS Soc 2020;23. doi:10.1002/jia2.25573.

[16] de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. J Virol 2013;87:7790–2. doi:10.1128/JVI.01244-13.

[17] Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814–20. doi:10.1056/NEJMoa1211721.

[18] Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012;17.

[19] Al-Tawfiq JA, Auwaerter PG. Healthcare-associated infections: the hallmark of Middle East respiratory syndrome coronavirus with review of the literature. J Hosp Infect 2019;101:20–9. doi:10.1016/j.jhin.2018.05.021.

[20] Hastings DL, Tokars JJ, Abdel Aziz IZAM, Alkhaldi KZ, Bensadek AT, Alraddadi BM, et al. Outbreak of Middle East Respiratory Syndrome at Tertiary Care Hospital, Jeddah, Saudi Arabia, 2014. Emerg Infect Dis 2016;22:794–801. doi:10.3201/eid2205.151797.

[21] Garout MA, Jokhdar HAA, Aljahdali IA, Zein AR, Goweda RA, Hassan-Hussein A.
Mortality rate of ICU patients with the middle east respiratory syndrome – Coronavirus infection at king Fahad hospital, Jeddah, Saudi Arabia. Cent Eur J Public Health 2018;26:87–91. doi:10.21101/cejph.a4764.

[22] Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome Coronavirus and Severe Acute Respiratory Syndrome Coronavirus. Semin Respir Crit Care Med 2020;41:568–78. doi:10.1055/s-0040-1709160.

[23] Barry M, AlMohaya AE, AlHijji A, Akkielah L, AlRajhi A, Almajid F, et al. Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients in a MERS-CoV Endemic Area. J Epidemiol Glob Health 2020;10:214–21. doi:10.2991/jegh.k.200806.002.

[24] Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect Dis 2013;13:752–61. doi:10.1016/S1473-3099(13)70204-4.

[25] Al-Tawfiq JA, Hinedi K, Ghandour J, Khairalla H, Musleh S, Ujayli A, et al. Middle East Respiratory Syndrome-CoV: a case-control study of hospitalized patients. Clin Infect Dis 2014;59:160–5. doi:10.1093/cid/ciu226.

[26] ALJishi JM, Al-Tawfiq JA. Intermittent viral shedding in respiratory samples of patients with SARS-CoV-2: observational analysis with infection control implications. J Hosp Infect 2020. doi:10.1016/j.jhin.2020.09.011.

[27] Al-Tawfiq JA, Garout MA, Gautret P. Preparing for emerging respiratory pathogens such as SARS-CoV, MERS-CoV, and SARS-CoV-2. Le Infez Med 2020;28:64–70.

[28] Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, Memish ZA. Middle East Respiratory Syndrome Coronavirus and Pulmonary Tuberculosis Coinfection: Implications for
Infection Control. Intervirology 2017;60:53–5. doi:DOI: 10.1159/000477908.

[29] Alfaraj SH, Al-Tawfiq JA, Alzahrani NA, Altwajri TA, Memish ZA. The impact of co-infection of influenza A virus on the severity of Middle East Respiratory Syndrome Coronavirus. J Infect 2017;74:521–3. doi:10.1016/j.jinf.2017.02.001.

[30] Ebrahim SH. Lack of MERS-CoV co-infection among hospitalized COVID-19 patients in Saudi Arabia. J Epidemiol Glob Health 2020;10:191. doi:10.2991/jegh.k.200819.001.

[31] Alsofayan YM, Althunayyan SM, Khan AA, Hakawi AM, Assiri AM. Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study. J Infect Public Health 2020;13:920–5. doi:10.1016/j.jiph.2020.05.026.

[32] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020. doi:10.1016/S0140-6736(20)30183-5.

[33] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc 2020;323:1061–9. doi:10.1001/jama.2020.1585.

[34] Al Bahrani SY, Al-Tawfiq JA, Alshaer AR, Shilash A, Alswefy K, Al-Zayer RS, et al. A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital. J Epidemiol Glob Health 2021. doi:10.2991/jegh.k.210112.001.

[35] Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014;29:301–6. doi:10.1016/j.ijid.2014.09.003.
[36] Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DAT, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013;369:407–16. doi:10.1056/NEJMoa1306742.

[37] Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014;160:389–97. doi:10.7326/M13-2486.

[38] Shalhoub S, Farahat F, Al-Jiffri A, Simhairi R, Shamma O, Siddiqi N, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015;70:2129–32. doi:10.1093/jac/dkv085.

[39] Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ 2020;369. doi:10.1136/bmj.m1985.

[40] Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 2020;288:335–44. doi:10.1111/joim.13089.

[41] Fagbo SF, Skakni L, Chu DKW, Garbati MA, Joseph M, Peiris M, et al. Molecular Epidemiology of Hospital Outbreak of Middle East Respiratory Syndrome, Riyadh, Saudi Arabia, 2014. Emerg Infect Dis 2015;21:1981–8. doi:10.3201/eid2111.150944.

[42] Al-Tawfiq JA, Alfaraj SH, Altuwaijri TA, Memish ZA. A cohort-study of patients suspected for MERS-CoV in a referral hospital in Saudi Arabia. J Infect 2017;75:378–9.
[43] Ahmed AE. The predictors of 3- and 30-day mortality in 660 MERS-CoV patients. BMC Infect Dis 2017;17:615. doi:10.1186/s12879-017-2712-2.

[44] Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med 2018;197:757–67. doi:10.1164/rccm.201706-1172OC.

[45] Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort study. Travel Med Infect Dis 2019. doi:10.1016/j.tmaid.2019.03.004.

[46] Nam H-S, Park JW, Ki M, Yeon M-Y, Kim J, Kim SW. High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea. Int J Infect Dis 2017. doi:10.1016/j.ijid.2017.02.008.

[47] Kim KH, Tandi TE, Choi JW, Moon JM, Kim MS. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect 2017;95:207–13. doi:10.1016/j.jhin.2016.10.008.

[48] Choi WS, Kang C-I, Kim Y, Choi J-P, Joh JS, Shin H-S, et al. Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea. Infect Chemother 2016;48:118–26. doi:10.3947/ic.2016.48.2.118.

[49] RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med 2020. doi:10.1056/nejmoa2021436.

[50] Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. Anaesthesia
[51] Omrani AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, Albarrak AM. A family cluster of middle east respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis 2013;17:e668-72. doi:10.1016/j.ijid.2013.07.001.

[52] Memish Z a, Zumla AI, Al-Hakeem RF, Al-Rabeeah A a, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013;368:2487–94. doi:10.1056/NEJMoa1303729.

[53] Memish ZA, Cotten M, Watson SJ, Kellam P, Zumla A, Alhakeem RF, et al. Community Case Clusters of Middle East Respiratory Syndrome Coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: A Descriptive Genomic study. Int J Infect Dis 2014;23:63–8. doi:10.1016/j.ijid.2014.03.1372.

[54] Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe 2021;2:e13–22. doi:10.1016/s2666-5247(20)30172-5.

[55] Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. Clin Infect Dis 2020. doi:10.1093/cid/ciaa460.

[56] Tirupathi R, Ramparas TR, Wadhwa G, Areti S, Kaur J, Salim S, et al. Viral dynamics in the Upper Respiratory Tract (URT) of SARS-CoV-2. Le Infecz Med 2020;28:486–99.

[57] Al-Tawfiq JA, Memish ZA. COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies. Int J Antimicrob Agents 2020;55. doi:10.1016/j.ijantimicag.2020.105968.
[58] Tirupathi R, Bharathidasan K, Palabindala V, Salim SA, Al-Tawfiq JA. Comprehensive review of mask utility and challenges during the COVID-19 pandemic. Le Infez Med 2020;28:57–63.

[59] Liang M, Gao L, Cheng C, Zhou Q, Uy JP, Heiner K, et al. Efficacy of face mask in preventing respiratory virus transmission: A systematic review and meta-analysis. Travel Med Infect Dis 2020;36. doi:10.1016/j.tmaid.2020.101751.
Table 1: Characteristics, Clinical Presentation and Outcome of ICU MERS-CoV and SARS-CoV-2 Coinfection

| Patient Number | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   |
|----------------|-----|-----|-----|-----|-----|-----|-----|-----|
| ICU LOS (days) | 18  | 7   | 12  | 21  | 8   | 3   | 11  | 7   |
| Hospital LOS (days) | 18  | 19  | 39  | 31  | 29  | 4   | 20  | 9   |
| Age (years)     | 48  | 36  | 36  | 39  | 33  | 52  | 69  | 42  |
| Gender          | male| male| male| female| male| male| female| male |
| Was patient Saudi or non-Saudi? | non-Saudi | non-Saudi | non-Saudi | non-Saudi | non-Saudi | non-Saudi | Saudi |
| BMI             | 32.8| 38.1| 31.9| 23.9| 29.0| 31.1| 35.2| 26.0|
| Was the case in close contact with a person with fever a/or cough who has been to an affected area? | not indicated | not indicated | not indicated | not indicated | not indicated | No | No | Yes |
| Current smoker  | no  | no  | no  | no  | unknown | no  | no  | no  |
| Condition                                      | No  | No  | No  | No  | No  | No  | No  | Yes | No  |
|-----------------------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Diabetes mellitus                             |     |     |     |     |     |     |     | yes | no  |
| Hypertension                                  |     |     |     |     |     |     |     |     |     |
| Ischemic heart disease                        |     |     |     |     |     |     |     |     |     |
| Heart failure (ejection fraction < 50%)        |     |     |     |     |     |     |     | yes | no  |
| Chronic Lung disease                          |     |     |     |     | unknown |     |     |     |     |
| Duration of symptoms prior to hospital admission | 1  | 4  | 4  | 2  | 2  | asymptomatic | 4  | 4  |    |
| Shortness of breath (Dyspnoea)                | yes | yes | yes | yes | yes | yes | yes | yes | yes |
| Runny nose (rhinorrhoea)                      | yes | unknown | no | no | unknown | no | yes | no  |    |
| Gastrointestinal symptoms                     | yes | unknown | no | no | unknown | yes | yes | yes |    |
| (Diarrhea/vomiting) | | | | | | | |
|---------------------|-----|-----|-----|-----|-----|-----|-----|
| History of fever    | yes | yes | yes | yes | yes | yes | no | yes |
| Altered consciousness/confusion | no | unknown | no | no | unknown | no | no | yes |
| Cough               | yes | yes | yes | yes | yes | yes | no | yes |
| Hospital Admission | 101 | 85 | 73 | 129 | 82 | 109 | 91 |
| Mean BP (mmHg)      |     |     |   |     |     |     |     |
| Heart rate (beats/minute) | 86 | 85 | 103 | 110 | 104 | 96 | 90 |
| Respiratory rate (breaths/minute) | 32 | 22 | 24 | 20 | 20 | 25 | 17 |
| Oxygen saturation (on room air) (%) | 75 | 81 | 88 | 96 | 88 | 94 | 98 |
| Temperature (highest within the first 24 hrs) (°C) | 38 | 38.3 | 38.1 | 39 | 39.6 | 37.2 | 38.6 |
| Glasgow Coma Score (GCS) | 15 | 15 | 15 | 10 | 15 | 15 | 15 | 15 |
|--------------------------|----|----|----|----|----|----|----|----|
| Chest X-ray - Consolidation | yes | no | yes | yes | yes | no | no | yes |
| Chest X-ray infiltrate on admission | bilateral | no | bilateral | bilateral | bilateral | no | no | bilateral |
| ICU admission PH value | 7.28 | 7.415 | 7.37 | 7.44 | 7.411 | 7.49 |
| PCO2 value (mmHg) | 55.9 | 41.1 | 36.1 | 39.9 | 36.6 | 51 |
| PaO2 value (mmHg) | 95.9 | 61.8 | 207 | 60 | 89 | 71 |
| O2 Saturation (%) | 96.6 | 91.7 | 99.8 | 93 | 97.7 | 99 | 91 |
| Intubated and mechanically ventilated | yes | yes | yes | yes | yes | yes | yes | no |
| Hospital discharge outcome | death | home | death | home | home | transferred | death | home |
**Table 2:** Initial mean and SD of laboratory tests

| Laboratory (normal range)                      | Mean and Standard Deviation of Data on Hospital Admission |
|-----------------------------------------------|---------------------------------------------------------|
| Hgb (13 to 17 mg/dl)                          | 13.12 (1.96)                                           |
| WBC (4-11 x 10⁹/L)                            | 8.29 (4.03)                                            |
| Absolute Lymphocyte (0.90-2.90 x 10⁹/L)       | 1.55 (1.23)                                            |
| Absolute Neutrophil (1.70-7 x 10⁹/L)          | 9.13 (3.26)                                            |
| Neutrophils/Lymphocyte ratio (1-3)             | 10.14 (8.77)                                           |
| Platelets (150-450 x 10⁹/L)                    | 247.4 (76.9)                                           |
| aPTT (30 to 40 seconds)                        | 32.23 (5.56)                                           |
Travel Medicine and Infectious Disease

Conflict of Interest Policy

Article Title:
Severe Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Coinfection: A Unique Case Series

Author name: Ahmad Mady

Declarations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest
A conflicting interest exists when professional judgement concerning a primary interest (such as patient’s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications registrations, and grants or other funding.

Please state any competing interests

None

Funding Source
All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

None

Signature (a scanned signature is acceptable,

Ahmad Mady
Travel Medicine and Infectious Disease

Conflict of Interest Policy

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest
A conflicting interest exists when professional judgement concerning a primary interest (such as patient’s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

None

Funding Source
All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

None

Signature (a scanned signature is acceptable,}

____  ______  _______  Awad Al-Omari
Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable): TMAID_
Article Title:
Severe Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Coinfection: A Unique Case Series

Author name: Alyaa Elhazmi

Declarations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest

A conflicting interest exists when professional judgement concerning a primary interest (such as patient’s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

None

Funding Source

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

None

Signature (a scanned signature is acceptable,

________________________  Alyaa Elhazmi ____________

16 Jan 2021
Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable): TMAID_
Article Title:
Severe Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Coinfection: A Unique Case Series

Author name: Saad Alhumaid

Declarations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest
A conflicting interest exists when professional judgement concerning a primary interest (such as patient’s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

None

Funding Source
All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

None

Signature (a scanned signature is acceptable,

Saad Alhumaid_
Travel Medicine and Infectious Disease

Conflict of Interest Policy

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest
A conflicting interest exists when professional judgement concerning a primary interest (such as patient’s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

None

Funding Source
All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

None

Signature (a scanned signature is acceptable, 

Abbas Al Mutair___
Travel Medicine and Infectious Disease

Conflict of Interest Policy

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest
A conflicting interest exists when professional judgement concerning a primary interest (such as patient’s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

None

Funding Source
All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

None

Signature (a scanned signature is acceptable,

Hend Sallam __
Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable): TMAID_
Article Title:
Severe Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Coinfection: A Unique Case Series

Author name: Jaffar A. Al-Tawfiq

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest
A conflicting interest exists when professional judgement concerning a primary interest (such as patient’s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

None

Funding Source
All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

None

Signature (a scanned signature is acceptable,

________________________ Jaffar A. Al-Tawfiq __